Solstice Neurosciences Report issue

Contributed to NME For profit Phase 4
Founded: Malvern PA United States (2003)
Status: Acquired by US WorldMeds (2010)

Organization Overview

First Clinical Trial
2003
NCT00702754
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Solstice Neurosciences | Solstice NeuroSciences, LLC

Active Ingredients

Marketed Drugs (1)

rimabotulinumtoxinB (Myobloc) (2000 NDA)

Drugs in Phase 4 Trials (1)

rimabotulinumtoxinB (Myobloc) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 4)

Brain Injuries (Phase 4)

Dystonia (Phase 4)

Dystonic Disorders (Phase 4)

Muscle Spasticity (Phase 4)

Parkinson Disease (Phase 2)

Sialorrhea (Phase 2)

Spinal Cord Injuries (Phase 4)

Torticollis (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 1